Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the primary biliary cholangitis market right now?

The primary biliary cholangitis market has seen rapid growth, expanding from $0.98 billion in 2024 to $1.09 billion in 2025, at a CAGR of 11.8%. Past growth was driven by increasing disease awareness, rising global healthcare expenditure, strategic collaborations, patient advocacy efforts, and government initiatives focused on liver health.

How fast Is the primary biliary cholangitis market expected to grow, and what’s its future value?

The primary biliary cholangitis market is expected to see strong growth, reaching $1.6 billion by 2029, with a CAGR of 9.9%. Growth will be driven by biomarker research, rare disease management efforts, clinical trial collaborations, patient-focused care, and rising liver transplant demand. Trends include biomarker advancements, non-invasive diagnostics, immunomodulatory therapy research, AI integration, patient-reported clinical outcomes, telemedicine, and combination therapies.

Get your primary biliary cholangitis market report here!

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

What are the leading drivers of growth in the primary biliary cholangitis market?

The primary biliary cholangitis market is poised for growth, spurred on by the rising prevalence of smoking. This act entails the inhalation and exhalation of smoke from burning tobacco or other substances. It’s recognized that smoking is a risk factor for liver diseases, inclusive of PBC, and a rise in smoking will result in a greater number of people seeking healthcare for liver-related conditions. For example, government agency, Statistics Canada, reported that cigarette production in July 2023 witnessed an increase by 2.2% from June 2023, and there was a 2.6% uptick in cigarette sales in the same month, reaching 1.4 billion units. Therefore, the primary biliary cholangitis market is set to benefit from increasing smoking rates.

Primary Biliary Cholangitis Market Driver: Increase in Liver Cancer Cases Boosts Growth in Primary Biliary Cholangitis Market

What are the key segments defining the primary biliary cholangitis market?

The primary biliary cholangitis market covered in this report is segmented –

1) By Treatment Type: Drugs, Liver Transplantation

2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses

3) By End-Users: Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies

2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

Who are the key players steering the development of the primary biliary cholangitis market?

Major companies operating in the primary biliary cholangitis market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Vertex Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac N.V., Sangamo Therapeutics Inc., Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc., Bluebird Bio Inc., Intellia Therapeutics Inc., Albireo Pharma Inc., TARGET PharmaSolutions Inc., Genfit S.A., Editas Medicine Inc., CymaBay Therapeutics Inc., Ascletis Pharma Inc.

What emerging trends are influencing the growth of the primary biliary cholangitis market?

Organizations operating within the primary biliary cholangitis market are aiming to carve out an exclusive niche for themselves by creating specialized and novel treatments. These include a mix of obeticholic acid (OCA) and bezafibrates, designated as orphan drugs, aimed specifically at tackling primary biliary cholangitis (PBC). The objective is to offer a comprehensive and superior method of managing PBC, increasing the potential to enhance the quality of life for those suffering from this uncommon disease. For instance, Intercept Pharmaceuticals, Inc., a biopharmaceutical entity from the US, was granted the status of an orphan drug by the FDA in May 2023. This was for the combined use of obeticholic acid (OCA) and bezafibrate, a PPAR agonist, as a possible means of treating primary biliary cholangitis (PBC), a degenerative liver disease. The US has approved the use of obeticholic acid (known in the market as Ocaliva) for PBC treatment.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13520

Which regions are most influential in expanding the primary biliary cholangitis market?

North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Neuropathic Pain Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

Pituitary Dwarf Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pituitary-dwarf-treatment-global-market-report

Myelodysplastic Syndrome Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: